Novel bi-specific TCR-based reagents for targeted cancer immunotherapy

Centrosomes in ovarian cancer

Hallmarks of cancer cell development

What is the WIN Consortium?

Pembrolizumab and indoximod for melanoma

Projections of cancer incidence and burden among the HIV-positive population in the United States through 2030

Nivolumab for NSCLC: five years on

Avelumab for metastatic Merkel cell carcinoma after chemotherapy

Nivolumab and ipilimumab combination for advanced skin cancer

Long-term clinical outcomes and analyses of atezolizumab for mTNBC

Checkmate 067 - combined nivolumab and ipilimumab

IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors